Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.
While rates of scurvy are nowhere near as high as they once were, the vitamin C deficiency best known for plaguing sailors during long voyages is still around. When cases do emerge, they can offer ...